KR20140115239A - 파킨슨병 치료용 시스타민 유사체 - Google Patents

파킨슨병 치료용 시스타민 유사체 Download PDF

Info

Publication number
KR20140115239A
KR20140115239A KR1020137024680A KR20137024680A KR20140115239A KR 20140115239 A KR20140115239 A KR 20140115239A KR 1020137024680 A KR1020137024680 A KR 1020137024680A KR 20137024680 A KR20137024680 A KR 20137024680A KR 20140115239 A KR20140115239 A KR 20140115239A
Authority
KR
South Korea
Prior art keywords
cystamine
analog
pharmaceutically acceptable
acceptable salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137024680A
Other languages
English (en)
Korean (ko)
Inventor
프란체스카 치켓티
클로드 롤라드
프레드릭 칼롱
Original Assignee
유니버시티 라발
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 라발 filed Critical 유니버시티 라발
Publication of KR20140115239A publication Critical patent/KR20140115239A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137024680A 2011-02-23 2012-02-23 파킨슨병 치료용 시스타민 유사체 Ceased KR20140115239A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161445577P 2011-02-23 2011-02-23
CA2732440A CA2732440C (en) 2011-02-23 2011-02-23 Cystamine analogues for the treatment of parkinson`s disease
US61/445,577 2011-02-23
CA2,732,440 2011-02-23
PCT/CA2012/050106 WO2012113079A1 (en) 2011-02-23 2012-02-23 Cystamine analogues for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
KR20140115239A true KR20140115239A (ko) 2014-09-30

Family

ID=46717621

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137024680A Ceased KR20140115239A (ko) 2011-02-23 2012-02-23 파킨슨병 치료용 시스타민 유사체

Country Status (11)

Country Link
US (1) US20140073694A1 (enExample)
EP (1) EP2678009B1 (enExample)
JP (1) JP6000985B2 (enExample)
KR (1) KR20140115239A (enExample)
CN (1) CN103442704A (enExample)
AU (1) AU2012220314B2 (enExample)
BR (1) BR112013021616A2 (enExample)
CA (1) CA2732440C (enExample)
MX (1) MX350195B (enExample)
RU (1) RU2630583C2 (enExample)
WO (1) WO2012113079A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659209B (zh) * 2013-06-17 2019-05-11 地平線罕見醫學製藥有限責任公司 分析半胱胺組合物的方法
TW201618760A (zh) * 2014-11-05 2016-06-01 雷普特製藥有限公司 使用半胱胺組合物治療亨廷頓氏病之方法
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
RU2766579C2 (ru) 2015-07-02 2022-03-15 ХОРАЙЗОН ОРФАН ЭлЭлСи Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение
WO2017166139A1 (zh) 2016-03-30 2017-10-05 广东欧珀移动通信有限公司 中继传输的方法和装置
WO2020198529A1 (en) * 2019-03-26 2020-10-01 The Regents Of The University Ofcalifornia Substituted amino-thiol and amino-disulfide compounds, and uses thereof
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN119909064B (zh) * 2025-04-07 2025-08-15 北京大学深圳研究生院 胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用
CN120437102B (zh) * 2025-07-09 2025-09-16 中南大学湘雅医院 胱胺在制备治疗脓毒症脑病药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211624A1 (en) * 2003-02-02 2006-09-21 Goverment of the US, as Represented by Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies
RU2255775C1 (ru) * 2003-12-25 2005-07-10 Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук Способ лечения болезни паркинсона
WO2007089670A2 (en) * 2006-01-27 2007-08-09 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
WO2008143876A2 (en) * 2007-05-14 2008-11-27 The Trustees Of Columia University In The City Of New York Agents and assays for modulating neurodegeneration
EP2296462A4 (en) * 2008-06-13 2011-06-15 Teva Pharma RASAGILINE FOR INFLUENCING MORBUS PARKINSON

Also Published As

Publication number Publication date
BR112013021616A2 (pt) 2020-09-29
US20140073694A1 (en) 2014-03-13
MX350195B (es) 2017-08-30
AU2012220314A1 (en) 2013-08-22
EP2678009A1 (en) 2014-01-01
JP2014508758A (ja) 2014-04-10
RU2013137645A (ru) 2015-02-20
MX2013009608A (es) 2013-09-16
WO2012113079A1 (en) 2012-08-30
EP2678009A4 (en) 2014-08-06
AU2012220314B2 (en) 2017-04-06
CN103442704A (zh) 2013-12-11
CA2732440A1 (en) 2012-08-23
EP2678009B1 (en) 2017-11-01
CA2732440C (en) 2017-10-31
RU2630583C2 (ru) 2017-09-11
JP6000985B2 (ja) 2016-10-05

Similar Documents

Publication Publication Date Title
AU2012220314B2 (en) Cystamine analogues for the treatment of Parkinson&#39;s disease
Edison Astroglial activation: Current concepts and future directions
Du et al. Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson’s disease
Ossola et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GNDF in astroglia
Eid et al. Glutamate and astrocytes—key players in human mesial temporal lobe epilepsy?
Wu et al. Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer's disease
Huh et al. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson’s disease
Facheris et al. Peripheral markers of oxidative stress and excitotoxicity in neurodegenerative disorders: tools for diagnosis and therapy?
Mahan Neuroprotective, neurotherapeutic, and neurometabolic effects of carbon monoxide
CN103189056A (zh) L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗
Galuppo et al. Anti-inflammatory and anti-apoptotic effects of (RS)-glucoraphanin bioactivated with myrosinase in murine sub-acute and acute MPTP-induced Parkinson’s disease
Sun et al. SIRT1 activation attenuates microglia-mediated synaptic engulfment in postoperative cognitive dysfunction
Kosonen et al. Role of agmatine in the application of neural progenitor cell in central nervous system diseases: therapeutic potentials and effects
Zhu et al. Intermittent Theta Burst Stimulation Attenuates Cognitive Deficits and Alzheimer’s Disease-Type Pathologies via ISCA1-Mediated Mitochondrial Modulation in APP/PS1 Mice: Y. Zhu et al.: Intermittent Theta Burst Stimulation Attenuates Cognitive Deficits
Liu et al. D-serine ameliorates motor and cognitive impairments in β-amyloid 1-42 injected mice by inhibiting JNK signaling pathway
Shin et al. Ceruloplasmin is an endogenous protectant against kainate neurotoxicity
Wang et al. Phytic acid attenuates upregulation of GSK-3β and disturbance of synaptic vesicle recycling in MPTP-induced Parkinson's disease models
JP2018513204A (ja) 神経保護および神経変性の治療のための組成物および方法
GB2571978A (en) Uses, compositions and methods
CN101316584A (zh) 用于预防及治疗由血管通透性亢进引起的眼病的医药
Kovács et al. Neuroprotective and Behavioral Benefits of Exogenous Ketone Supplementation-Evoked Ketosis
Tulimiero et al. Diaphragm‐specific effects of L‐citrulline in mdx mice highlight its potential as adjuvant of standard therapy in Duchenne muscular dystrophy
Tiwari et al. Delineating the Neuroinflammatory Crosstalk in Neurodegeneration and Probing the Near Future Therapeutics
Mullins BT2 as a novel therapeutic compound for Alzheimer’s disease
ES2377381A1 (es) Uso de una combinación de n-acetil-cisteína y ácido lipoico para la preparación de un medicamento útil para el tratamiento de una enfermedad con daño axonal y lesiones oxidativas concomitantes.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130917

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170113

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171201

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180627

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171201

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I